112 related articles for article (PubMed ID: 21723741)
1. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials.
Liu L; Stadheim A; Hamuro L; Pittman T; Wang W; Zha D; Hochman J; Prueksaritanont T
Biologicals; 2011 Jul; 39(4):205-10. PubMed ID: 21723741
[TBL] [Abstract][Full Text] [Related]
2. Optimization of humanized IgGs in glycoengineered Pichia pastoris.
Li H; Sethuraman N; Stadheim TA; Zha D; Prinz B; Ballew N; Bobrowicz P; Choi BK; Cook WJ; Cukan M; Houston-Cummings NR; Davidson R; Gong B; Hamilton SR; Hoopes JP; Jiang Y; Kim N; Mansfield R; Nett JH; Rios S; Strawbridge R; Wildt S; Gerngross TU
Nat Biotechnol; 2006 Feb; 24(2):210-5. PubMed ID: 16429149
[TBL] [Abstract][Full Text] [Related]
3. Binding of DC-SIGN to glycoproteins expressed in glycoengineered Pichia pastoris.
Cukan MC; Hopkins D; Burnina I; Button M; Giaccone E; Houston-Cummings NR; Jiang Y; Li F; Mallem M; Mitchell T; Moore R; Nylen A; Prinz B; Rios S; Sharkey N; Zha D; Hamilton S; Li H; Stadheim TA
J Immunol Methods; 2012 Dec; 386(1-2):34-42. PubMed ID: 22982058
[TBL] [Abstract][Full Text] [Related]
4. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
[TBL] [Abstract][Full Text] [Related]
5. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
[TBL] [Abstract][Full Text] [Related]
6. Production of monoclonal antibodies by glycoengineered Pichia pastoris.
Potgieter TI; Cukan M; Drummond JE; Houston-Cummings NR; Jiang Y; Li F; Lynaugh H; Mallem M; McKelvey TW; Mitchell T; Nylen A; Rittenhour A; Stadheim TA; Zha D; d'Anjou M
J Biotechnol; 2009 Feb; 139(4):318-25. PubMed ID: 19162096
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation characterization of recombinant human erythropoietin produced in glycoengineered Pichia pastoris by mass spectrometry.
Gong B; Burnina I; Stadheim TA; Li H
J Mass Spectrom; 2013 Dec; 48(12):1308-17. PubMed ID: 24338886
[TBL] [Abstract][Full Text] [Related]
8. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
9. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
10. Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production.
Ye J; Ly J; Watts K; Hsu A; Walker A; McLaughlin K; Berdichevsky M; Prinz B; Sean Kersey D; d'Anjou M; Pollard D; Potgieter T
Biotechnol Prog; 2011; 27(6):1744-50. PubMed ID: 22002933
[TBL] [Abstract][Full Text] [Related]
11. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
12. Production of Full-Length Antibody by Pichia pastoris.
Nylen A; Chen MT
Methods Mol Biol; 2018; 1674():37-48. PubMed ID: 28921426
[TBL] [Abstract][Full Text] [Related]
13. Production of sialylated O-linked glycans in Pichia pastoris.
Hamilton SR; Cook WJ; Gomathinayagam S; Burnina I; Bukowski J; Hopkins D; Schwartz S; Du M; Sharkey NJ; Bobrowicz P; Wildt S; Li H; Stadheim TA; Nett JH
Glycobiology; 2013 Oct; 23(10):1192-203. PubMed ID: 23893788
[TBL] [Abstract][Full Text] [Related]
14. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
[TBL] [Abstract][Full Text] [Related]
15. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
Zhang N; Liu L; Dumitru CD; Cummings NR; Cukan M; Jiang Y; Li Y; Li F; Mitchell T; Mallem MR; Ou Y; Patel RN; Vo K; Wang H; Burnina I; Choi BK; Huber HE; Stadheim TA; Zha D
MAbs; 2011; 3(3):289-98. PubMed ID: 21487242
[TBL] [Abstract][Full Text] [Related]
16. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris.
Ha S; Wang Y; Rustandi RR
MAbs; 2011; 3(5):453-60. PubMed ID: 22048694
[TBL] [Abstract][Full Text] [Related]
18. The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in Glycoengineered Pichia Pastoris.
Liu L; Gomathinayagam S; Hamuro L; Prueksaritanont T; Wang W; Stadheim TA; Hamilton SR
Pharm Res; 2013 Mar; 30(3):803-12. PubMed ID: 23135825
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
[TBL] [Abstract][Full Text] [Related]
20. A high-throughput purification of monoclonal antibodies from glycoengineered Pichia pastoris.
Jiang Y; Li F; Button M; Cukan M; Moore R; Sharkey N; Li H
Protein Expr Purif; 2010 Nov; 74(1):9-15. PubMed ID: 20447459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
